awards grant
- Circulating pro-inflammatory cytokines (cPIC) as biomarkers of gastrointestinal and genitourinary toxicity in patients undergoing pelvic radiotherapy for prostate cancer
- Investigation of Resveratrol as a radiation sensitizer in prostate cancer
- Metformin as an Adjunct to Radiotherapy for Non-Small Cell Lung Cancer (NSCLC). In depth pre-clinical analysis of metformin action in NSCLC
- Pilot studies to investigate metformin as an enhancer of radiation responses in lung cancer xenografts
- [CCRA provided] Evaluation of repurposing a new diabetes drug as a radio-sensitizer for prostate cancer and in vivo studies to accelerate translation to clinical trials